ADCE-T02 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that cannot be removed by surgery and has grown despite at least one prior cancer treatment.
- You have at least one tumor that can be measured on a scan (per RECIST criteria).
- You are in good enough health to care for yourself (ECOG 0-1) and expected to live at least 3 months.
- Your major organs (like liver, kidney, bone marrow) are working well, as shown by lab tests.
- You agree to use effective birth control if you are of childbearing potential (women) or are a man who agrees to use condoms during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called ADCE-D01 for people with soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if it is safe and effective.
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.